Examining EXAMINE for an Interaction With Angiotensin-Converting Enzyme Inhibition.

about

Examining EXAMINE for an Interaction With Angiotensin-Converting Enzyme Inhibition.

Item

http://www.wikidata.org/entity/Q41907589

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Examining EXAMINE for an Interaction With Angiotensin-Converting Enzyme Inhibition.

@en

type

Item

label

Examining EXAMINE for an Interaction With Angiotensin-Converting Enzyme Inhibition.

@en

prefLabel

Examining EXAMINE for an Interaction With Angiotensin-Converting Enzyme Inhibition.

@en

P1476

Examining EXAMINE for an Interaction With Angiotensin-Converting Enzyme Inhibition.

@en

P2093

Jessica R Wilson

http://www.w3.org/2001/XMLSchema#string

Nancy J Brown

http://www.w3.org/2001/XMLSchema#string

P2860

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.

Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm

Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans.

Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition.

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.

P304

549-551

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1161/HYPERTENSIONAHA.116.07884

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27480841

http://www.w3.org/2001/XMLSchema#string

P932

4982800

http://www.w3.org/2001/XMLSchema#string